These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26039556)

  • 21. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
    Metro G; Crinò L
    Expert Rev Anticancer Ther; 2011 May; 11(5):673-82. PubMed ID: 21554040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
    Teh BW; Worth LJ
    Intern Med J; 2012 Nov; 42(11):1269-70. PubMed ID: 23157525
    [No Abstract]   [Full Text] [Related]  

  • 24. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
    Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
    Kishi K; Nakata K; Yoshimura K
    J Thorac Oncol; 2006 Sep; 1(7):733-4. PubMed ID: 17409949
    [No Abstract]   [Full Text] [Related]  

  • 27. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
    Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
    Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
    [No Abstract]   [Full Text] [Related]  

  • 28. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.
    Zaarour M; Weerasinghe C; Nazha B; Hassan S; Atallah JP
    Expert Rev Anticancer Ther; 2015; 15(11):1327-36. PubMed ID: 26414352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
    Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
    Köhler J; Schuler M
    Future Oncol; 2014 Mar; 10(4):533-40. PubMed ID: 24754585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
    Zhang PL; Chen L
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890
    [No Abstract]   [Full Text] [Related]  

  • 32. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
    Siegel-Lakhai WS; Beijnen JH; Schellens JH
    Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erlotinib: optimizing therapy with predictors of response?
    Goodin S
    Clin Cancer Res; 2006 May; 12(10):2961-3. PubMed ID: 16707589
    [No Abstract]   [Full Text] [Related]  

  • 35. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
    Zhou CC; Deng XF
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
    [No Abstract]   [Full Text] [Related]  

  • 37. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

  • 38. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological and clinical profile of afatinib (Giotrif®)].
    Takahashi N; Suzuki S; Sakai K; Azuma H
    Nihon Yakurigaku Zasshi; 2015 Feb; 145(2):100-6. PubMed ID: 25747022
    [No Abstract]   [Full Text] [Related]  

  • 40. Pulmonary fibrosis in a patient treated with erlotinib.
    Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
    Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.